← Leaderboards
Brian Andrew Pollok
Propagenix, Inc.
$740,366
Attributed
$740,366
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $263.2K · FY2017–21$500K$375K$250K$125K$0
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$740,366 · 3
By mechanism
R43$740,366 · 3
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Cells”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$155,695,588
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Evan Z Macosko · Broad Institute, Inc.$33,096,828
- James Dale Berry · Brigham And Women'S Hospital$30,122,905
- Hanjoon Ryu$28,519,898
- Eric C Palm · Florida State University$26,502,247
Research focus
CellsIn VitroTissuesSamplingPublic HealthCell Culture TechniquesResponseTechnologyEpithelial CellsMolecularIn VivoIn Vitro ModelLungLung DiseasesLiquid SubstanceNoseExhibitsData SetApplications GrantsEfficacy TestingEpithelialGene ExpressionCell SurvivalCell Type
Grant awards (3)
A Commercially Durable Biobank of Genetically Diverse and Differentiation Competent Primary Airway Progenitor Cells Validated for In Vitro Toxicology Screening$252,131
R43 · FY2021 · ES · contact PI
HLS-Applying EpiX⢠technology to enable ex vivo theratyping using nasal brushing samples from CF patients$263,235
R43 · FY2018 · HL · contact PI
Enhancement of Conditional Reprogramming Technology for Production of Functional Human Beta-Cells$225,000
R43 · FY2017 · DK · contact PI